Investigation Report on China Duloxetine Market, 2009-2018
Depression is a common mood disorder that belongs to high-incidence mental diseases worldwide. Its main clinical features are a state of low mood and aversion to activity, and sometimes even suicidal thoughts or behaviors.
According to statistics from World Health Organization (WHO), depression is one of the most disabling diseases in the world today with over 0.3 billion sufferers worldwide. Because there are 10 to 20 million patients with suicidal thoughts every year in the world, it is said that 21 century is a 'Century of Depression'. China is going through social transformation, which is also a period with high incidence of psychological problems. Statistics shows that there are more than 30 million depression patients now in China, of which over 80% have never been treated because of low income or other issues. Depression patients take up 50% to 70% of suicides and attempted suicides in China. Obviously, depression has become a major social problem in China.
Since Eli Lilly and Company first launched duloxetine (brand name 'Cymbalta') in August 2004, its sales revenue has been continually increasing, which nearly reached USD 5 billion in 2012.
The success of duloxetine sales also comes from its persistent exploration and study into indications. It is approved to treat adult depression by FDA and EU in August and September 2004 respectively. In September 2004 FDA approved its treatment for new important indications of diabetic peripheral neuropathic pain, making it the first drug approved for these diseases. In August 2004 duloxetine was also approved to cure women patients who lack effective treatment of moderate - severe stress urinary incontinence symptoms. Duloxetine was also authorized to treat fibromyalgia in June 2008 and chronic musculoskeletal pain in November 2010 by FDA. It is this constant innovation that makes duloxetine produced by Eli Lilly and Company best selling antidepressant worldwide. Before patent of duloxetine expired at the end of 2013, almost all famous general drug manufacturers planed to seize this great opportunity. In recent years, some pharmaceutical companies have earned provisional approvals issued by FDA.
Many manufacturers did not report the production of raw materials and preparation until 2005. However, only Shanghai Zhongxi Pharmaceutical Co., Ltd. successfully produced generic drug before duloxetine was under administrative protection, and was given the production approval of enteric-coated capsules and enteric-coated tablets. In present Chinese market, only Eli Lilly and Company and Shanghai Zhongxi Pharmaceutical Co., Ltd. are approved to sell duloxetine products. Yet in July 2013, some other manufacturers received drug registration approval of duloxetine APIs and enteric-coated tablet issued by FDA, whose products are expected to go on the market in 2014.
In China, antidepressants are still niche products. According to CRI's investigation, market size of antidepressant in China was less than CNY 4 billion in 2013. Main cause of current situation is society's lack of understanding of depression, which discourages patients from psychiatric treatment because of the prejudice. Another reason is people's lack of knowledge about depression. When depression occurs, people may consider it as emotional problems and miss the best time for medical treatment, leading to further deterioration. Low market demand leads to slow development of antidepressants by drug manufacturers. However, as Chinese society develops and people's living standard improves, Chinese people would require spiritual life of higher quality, which bestows antidepressant market a promising future. Market size of duloxetine therefore will soon increase rapidly.
Through this report, the readers can acquire the following information:
According to statistics from World Health Organization (WHO), depression is one of the most disabling diseases in the world today with over 0.3 billion sufferers worldwide. Because there are 10 to 20 million patients with suicidal thoughts every year in the world, it is said that 21 century is a 'Century of Depression'. China is going through social transformation, which is also a period with high incidence of psychological problems. Statistics shows that there are more than 30 million depression patients now in China, of which over 80% have never been treated because of low income or other issues. Depression patients take up 50% to 70% of suicides and attempted suicides in China. Obviously, depression has become a major social problem in China.
Since Eli Lilly and Company first launched duloxetine (brand name 'Cymbalta') in August 2004, its sales revenue has been continually increasing, which nearly reached USD 5 billion in 2012.
The success of duloxetine sales also comes from its persistent exploration and study into indications. It is approved to treat adult depression by FDA and EU in August and September 2004 respectively. In September 2004 FDA approved its treatment for new important indications of diabetic peripheral neuropathic pain, making it the first drug approved for these diseases. In August 2004 duloxetine was also approved to cure women patients who lack effective treatment of moderate - severe stress urinary incontinence symptoms. Duloxetine was also authorized to treat fibromyalgia in June 2008 and chronic musculoskeletal pain in November 2010 by FDA. It is this constant innovation that makes duloxetine produced by Eli Lilly and Company best selling antidepressant worldwide. Before patent of duloxetine expired at the end of 2013, almost all famous general drug manufacturers planed to seize this great opportunity. In recent years, some pharmaceutical companies have earned provisional approvals issued by FDA.
Many manufacturers did not report the production of raw materials and preparation until 2005. However, only Shanghai Zhongxi Pharmaceutical Co., Ltd. successfully produced generic drug before duloxetine was under administrative protection, and was given the production approval of enteric-coated capsules and enteric-coated tablets. In present Chinese market, only Eli Lilly and Company and Shanghai Zhongxi Pharmaceutical Co., Ltd. are approved to sell duloxetine products. Yet in July 2013, some other manufacturers received drug registration approval of duloxetine APIs and enteric-coated tablet issued by FDA, whose products are expected to go on the market in 2014.
In China, antidepressants are still niche products. According to CRI's investigation, market size of antidepressant in China was less than CNY 4 billion in 2013. Main cause of current situation is society's lack of understanding of depression, which discourages patients from psychiatric treatment because of the prejudice. Another reason is people's lack of knowledge about depression. When depression occurs, people may consider it as emotional problems and miss the best time for medical treatment, leading to further deterioration. Low market demand leads to slow development of antidepressants by drug manufacturers. However, as Chinese society develops and people's living standard improves, Chinese people would require spiritual life of higher quality, which bestows antidepressant market a promising future. Market size of duloxetine therefore will soon increase rapidly.
Through this report, the readers can acquire the following information:
- Incidence of Depression in China
- Market Share of Major Duloxetine Manufacturers in Sample Hospitals in China
- Sales price of Duloxetine in Hospital Market in China
- Production Status of Duloxetine Generic Drug in China
- Major Duloxetine Manufacturers in China
- Share of Duloxetine in Different Dosage Forms in China Hospital Market
- Prospect of China Duloxetine Market
- Antidepressant APIs and Finished Product Manufacturers
- Medical Institutions
- Investors /Research Agencies Focusing on China Antidepressant Market
1 RELEVANT CONCEPTS OF DULOXETINE
1.1 Indication
1.2 Sales Status on the Global Market
2 MARKET OVERVIEW OF DULOXETINE IN CHINA
2.1 Patent Status
2.2 Production Status of Generic Drug
2.3 Major Manufacturers
2.4 Market Size
3 INVESTIGATION ON SALES VALUE OF DULOXETINE IN CHINA, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region
4 INVESTIGATION ON MARKET SHARE OF MAJOR DULOXETINE MANUFACTURERS IN CHINA, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 INVESTIGATION ON MARKET SIZE OF DULOXETINE BY DOSAGE FORM IN CHINA, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form
6 REFERENCE PRICE OF DULOXETINE IN HOSPITAL MARKET IN CHINA, 2013
6.1 Price of Duloxetine (Cymbalta) Produced by Eli Lilly and Company in China Hospitals
6.2 Price of Duloxetine (Ao Siping) Produced by Shanghai Zhongxi Pharmaceutical Co., Ltd. in China Hospitals
7 MAJOR MANUFACTURING ENTERPRISES IN CHINA DULOXETINE MARKET, 2009-2013
7.1 Eli Lilly and Company
7.2 Shanghai Zhongxi Pharmaceutical Co., Ltd.
8 PROSPECT OF CHINA DULOXETINE MARKET, 2014-2018
8.1 Prediction of Depression Incidence in China
8.2 Research Status of Generic Drug
8.3 Forecast on Market Size
8.4 Forecast on Competition Pattern
1.1 Indication
1.2 Sales Status on the Global Market
2 MARKET OVERVIEW OF DULOXETINE IN CHINA
2.1 Patent Status
2.2 Production Status of Generic Drug
2.3 Major Manufacturers
2.4 Market Size
3 INVESTIGATION ON SALES VALUE OF DULOXETINE IN CHINA, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region
4 INVESTIGATION ON MARKET SHARE OF MAJOR DULOXETINE MANUFACTURERS IN CHINA, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 INVESTIGATION ON MARKET SIZE OF DULOXETINE BY DOSAGE FORM IN CHINA, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form
6 REFERENCE PRICE OF DULOXETINE IN HOSPITAL MARKET IN CHINA, 2013
6.1 Price of Duloxetine (Cymbalta) Produced by Eli Lilly and Company in China Hospitals
6.2 Price of Duloxetine (Ao Siping) Produced by Shanghai Zhongxi Pharmaceutical Co., Ltd. in China Hospitals
7 MAJOR MANUFACTURING ENTERPRISES IN CHINA DULOXETINE MARKET, 2009-2013
7.1 Eli Lilly and Company
7.2 Shanghai Zhongxi Pharmaceutical Co., Ltd.
8 PROSPECT OF CHINA DULOXETINE MARKET, 2014-2018
8.1 Prediction of Depression Incidence in China
8.2 Research Status of Generic Drug
8.3 Forecast on Market Size
8.4 Forecast on Competition Pattern
SELECTED CHARTS
Chart Duloxetine Products Approved to Market in China by 2014
Chart Sales Value of Duloxetine in Global Market, 2009-2013
Chart Sales Value of Duloxetine in Hospital Market in China, 2009-2013
Chart Sales Value of Duloxetine by Region in China, 2009-2013
Chart Market Share of Duloxetine Enterprises by Sales Value in China, 2009-2013
Chart Price of Duloxetine Produced by Fujisawa (IR) in China Hospital Market, 2013
Chart Price of Cymbalta in China Hospital Market, 2013
Chart Forecast on Market Size of Hospital-use Duloxetine in China, 2014-2018
Chart Provisional Approval of Duloxetine Issued by FDA
Chart Sales Value of Cymbalta in Global Market, 2008-2013
Chart Duloxetine Products Approved to Market in China by 2014
Chart Sales Value of Duloxetine in Global Market, 2009-2013
Chart Sales Value of Duloxetine in Hospital Market in China, 2009-2013
Chart Sales Value of Duloxetine by Region in China, 2009-2013
Chart Market Share of Duloxetine Enterprises by Sales Value in China, 2009-2013
Chart Price of Duloxetine Produced by Fujisawa (IR) in China Hospital Market, 2013
Chart Price of Cymbalta in China Hospital Market, 2013
Chart Forecast on Market Size of Hospital-use Duloxetine in China, 2014-2018
Chart Provisional Approval of Duloxetine Issued by FDA
Chart Sales Value of Cymbalta in Global Market, 2008-2013
